![Fred van Leuven](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fred van Leuven
Corporate Officer/Principal chez
Katholieke Universiteit Leuven
Profil
Fred van Leuven is the founder of AC Immune SA, founded in 2003, and reMYND NV, founded in 2002.
Dr. van Leuven currently holds the position of Professor at Katholieke Universiteit Leuven.
Dr. van Leuven earned a doctorate degree from Ghent University in 1976 and a graduate degree from Ghent University in 1970.
Postes actifs de Fred van Leuven
| Sociétés | Poste | Début |
|---|---|---|
Katholieke Universiteit Leuven
 Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Anciens postes connus de Fred van Leuven
| Sociétés | Poste | Fin |
|---|---|---|
| AC IMMUNE SA | Fondateur | - |
reMYND NV
 reMYND NV Miscellaneous Commercial ServicesCommercial Services Engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders | Fondateur | - |
Formation de Fred van Leuven
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
53
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
AC Immune SA
 AC Immune SA Pharmaceuticals: MajorHealth Technology Manufactures precision medicines for neurodegenerative diseases | Health Technology |
Ghent University
 Ghent University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Katholieke Universiteit Leuven
Katholieke Universiteit Leuven Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
reMYND NV
reMYND NV Miscellaneous Commercial ServicesCommercial Services Engages in the development of disease-modifying treatments against alzheimer's, parkinson's, diabetes and other protein misfolding disorders | Commercial Services |
